JP2009529657A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529657A5
JP2009529657A5 JP2008555179A JP2008555179A JP2009529657A5 JP 2009529657 A5 JP2009529657 A5 JP 2009529657A5 JP 2008555179 A JP2008555179 A JP 2008555179A JP 2008555179 A JP2008555179 A JP 2008555179A JP 2009529657 A5 JP2009529657 A5 JP 2009529657A5
Authority
JP
Japan
Prior art keywords
protein
cross
collection
igiv
misfolded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008555179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529657A (ja
Filing date
Publication date
Priority claimed from EP06075355A external-priority patent/EP1820806A1/en
Application filed filed Critical
Publication of JP2009529657A publication Critical patent/JP2009529657A/ja
Publication of JP2009529657A5 publication Critical patent/JP2009529657A5/ja
Pending legal-status Critical Current

Links

JP2008555179A 2006-02-16 2007-02-16 アフィニティ領域 Pending JP2009529657A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06075355A EP1820806A1 (en) 2006-02-16 2006-02-16 Affinity regions
PCT/NL2007/050063 WO2007094668A1 (en) 2006-02-16 2007-02-16 Affinity regions

Publications (2)

Publication Number Publication Date
JP2009529657A JP2009529657A (ja) 2009-08-20
JP2009529657A5 true JP2009529657A5 (cg-RX-API-DMAC7.html) 2010-04-15

Family

ID=36792791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008555179A Pending JP2009529657A (ja) 2006-02-16 2007-02-16 アフィニティ領域

Country Status (9)

Country Link
US (1) US20090155254A1 (cg-RX-API-DMAC7.html)
EP (2) EP1820806A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009529657A (cg-RX-API-DMAC7.html)
CN (1) CN101421304A (cg-RX-API-DMAC7.html)
AU (1) AU2007215621A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0707848A2 (cg-RX-API-DMAC7.html)
CA (1) CA2642828A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007094668A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807630B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
WO2007008072A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. CROSS-ß STRUCTURE BINDING COMPOUNDS
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1907864A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US20100015126A1 (en) * 2006-03-17 2010-01-21 Martijn Frans Ben Gerard Gebbink Methods of Binding of Cross-Beta Structures By Chaperones
JP5229789B2 (ja) * 2007-02-27 2013-07-03 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
CA2716521A1 (en) 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid .beta. activity of intravenous immunoglobulin (ivig) in vitro
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
PL3191599T3 (pl) * 2014-09-11 2023-12-27 Board Of Regents Of The University Of Texas System Wykrywanie nieprawidłowo sfałdowanych białek
US20170329892A1 (en) * 2016-05-10 2017-11-16 Accutar Biotechnology Inc. Computational method for classifying and predicting protein side chain conformations
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113390836B (zh) * 2020-03-13 2023-09-29 吉林大学 硫磺素t的应用及一种牛奶中酪蛋白的检测方法
CN114441466B (zh) * 2020-11-04 2025-03-28 厦门红观生物科技有限公司 一种利用ApoJ抑制ApoB100热聚集的方法及定量检测ApoJ活性的方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
EP0319144A1 (en) * 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
EP0321703B1 (en) * 1987-11-20 1993-04-28 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Absorbent for serum amyloid protein
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
US5180615A (en) * 1989-12-13 1993-01-19 W.R. Grace & Co.-Conn. Metallized bag for static protection of electronic components
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5560418A (en) * 1993-04-02 1996-10-01 Advantage Office Systems, L.L.C. Attachment bar for partition panel
US5449663A (en) * 1993-06-11 1995-09-12 Bicher; Haim I. Antineoplastic compositions
US5935927A (en) * 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
US6410598B1 (en) * 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6310046B1 (en) * 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
WO1997026919A2 (en) * 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
US5785187A (en) * 1996-04-29 1998-07-28 Lipman; Daniel Mechandising display assembly
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
US6929807B1 (en) * 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
EP1014996B1 (en) * 1997-08-28 2003-05-28 University of Washington Saccharide-containing compositions for treating alzheimer's disease and other amyloidoses
CA2306875C (en) * 1997-10-24 2011-01-04 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
WO1999060024A1 (en) * 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
JP2001227537A (ja) * 2000-02-18 2001-08-24 Nsk Ltd 直動案内装置
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
HUP0300067A3 (en) * 2000-02-21 2010-03-29 Lundbeck & Co As H Novel method for down-regulation of amyloid
EP1130031A1 (en) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
EP1172378A1 (en) * 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP2264018B1 (en) * 2000-08-24 2015-02-11 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives for use in the diagnosis of Alzheimer's disease
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2453403C (en) * 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
JP2003024080A (ja) * 2001-07-19 2003-01-28 Univ Tokyo ｐ５３依存性アポトーシス誘導タンパク質、およびアポトーシス調節剤のスクリーニング方法
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20050142611A1 (en) * 2002-09-30 2005-06-30 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
EP1907864A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007008072A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. CROSS-ß STRUCTURE BINDING COMPOUNDS
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein

Similar Documents

Publication Publication Date Title
JP2009529657A5 (cg-RX-API-DMAC7.html)
CN1044121C (zh) 分离凝血因子viii配合物的方法
JP4803986B2 (ja) サンプル中のアルブミンを低減する装置および方法
Mahboob et al. Is isolation of comprehensive human plasma peptidomes an achievable quest?
JP2013511546A5 (cg-RX-API-DMAC7.html)
JP2015500502A5 (cg-RX-API-DMAC7.html)
Dørum et al. HLA-DQ molecules as affinity matrix for identification of gluten T cell epitopes
CN109651508A (zh) 异嗜性抗体阻断剂hbt-1及其制备方法
Mikkat et al. Comparison of accompanying proteins in different therapeutic human serum albumin preparations
Lei et al. Heparin chromatography to deplete high-abundance proteins for serum proteomics
CN106140099A (zh) 一种分离纯化乳铁蛋白的免疫亲和柱及其制备方法和用途
Kreuß et al. Separation of a glycosylated and non-glycosylated fraction of caseinomacropeptide using different anion-exchange stationary phases
CN115028682A (zh) 一种来源于干腌火腿的增咸肽及制备方法
JP2016512323A5 (cg-RX-API-DMAC7.html)
JP2024161359A (ja) 精製方法
CN105785037A (zh) 猪圆环病毒2型抗体快速检测层析试纸条及制备方法
KR102421918B1 (ko) 호산구 유래 신경독과 특이적으로 결합하는 단일클론항체 및 이의 용도
US9448243B2 (en) Weak affinity chromatography
EP3392265A1 (en) Methods for removing bacterial toxins from a biological fluid
CN101948535A (zh) 一种从鸡血中分离免疫球蛋白IgY的方法
US20090209737A1 (en) Use of denaturing agents during affinity capture
Ruprichová et al. Determination of proteins in yoghurt
JP5684969B2 (ja) インターフェロン療法の効果予測方法及び予測用キット
KR102200894B1 (ko) 피브리노겐 검출 센서 및 그의 제조방법
Wu et al. Development of immunoaffinity chromatographic method for Ara h 2 isolation